NEW YORK: AXIM Biotechnologies, Inc., a world leader in cannabinoid research and development, has entered clinical trials on treating irritable bowel syndrome (IBS) with the Company’s CanChew Plus cannabidiol (CBD) gum at Wageningen University in the Netherlands.
Human Clinical Trials Detail Include:
- Controlled-release hemp oil CBD chewing gum and matching placebo gums will be tested for the clinical studies
- The amount of the hemp oil CBD gum is set at 50mg of CBD per serving
- Per the trial protocol patients can use up to 6 chewing gums a day to control their stomach cramps, bloating, pain and other symptom
- The main study outcome is perceived pain reduction. Furthermore, the study will record general relief and change in stool frequenc
The clinical trial will include a group of 40 patients, age 18-65, diagnosed with IBS according to ROME III criteria to determine the effectiveness of CanChew Plus in alleviating IBS symptoms
“The clinical trial at Wageningen University is the first of its kind to treat IBS symptoms by cannabinoid-containing chewing gum, and we look forward to sharing updates from the trial with you,” added Anastassov.
“With positive outcome from the IBS clinical trial, we will be ready to proceed immediately with further trials on our pharmaceutical grade CanChew Rx products to treat inflammatory bowel disease (IBD); Ulcerative colitis and Crohn’s disease. We are committed to finding research-based cannabinoid